Imamura Chiyo

Researcher

基本情報

Profile and Settings

• 氏名

  Imamura Chiyo

Affiliation

• Advanced Cancer Translational Research Institute, Visiting Professor

Location

• Hatanodai Campus

Degree

• Doctor of Pharmaceutical Science, Kumamoto University, Mar. 2000

Achievements

Published Papers

• Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan Society of Clinical Oncology., 2. Hayashi T, Yamamoto S, Miyata Y, Takeda M, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iihara H., Int J Clin Oncol, Sep. 2024, Peer-reviewed
• Significance of the comprehensive geriatric assessment in the administration of chemotherapy to older adults with cancer: Recommendations by the Japanese Geriatric Oncology Guideline Committee., Kiichiro Ninomiya; Daisuke Inoue; Ken Sugimoto; Chie Tanaka; Keiko Murofushi; Toru Okuyama; Shigeaki Watanuki; Chiyo K Imamura; Daisuke Sakai; Naomi Sakurai; Kiyotaka Watanabe; Kazuo Tamura; Toshiaki Saeki; Hiroshi Ishiguro, Journal of geriatric oncology, 14(5):101485 - 101485, Apr. 2023, Peer-reviewed
• Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients., Hirotsugu Kenmotsu; Chiyo K Imamura; Takahisa Kawamura; Takuya Oyakawa; Shota Omori; Kazuhisa Nakashima; Kazushige Wakuda; Akira Ono; Tetsuhiko Taira; Tateaki Naito; Haruyasu Murakami; Nobuyuki Yamamoto; Toshiaki Takahashi; Yusuke Tanigawara, Cancer chemotherapy and pharmacology, Jul. 2022
• Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials., Eisuke Booka; Chiyo K Imamura; Masashi Takeuchi; Hirofumi Kawakubo; Hiroya Takeuchi; Yusuke Tanigawara; Yuko Kitagawa; Narikazu Boku, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, Mar. 2022
• A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy, Yuya Hirasawa; Kiyoshi Yoshimura; Hiroto Matsui; Yutaro Kubota; Hiroo Ishida; Jun Arai; Masashi Sakaki; Nao Oguro; Midori Shida; Makoto Taniguchi; Kazuyuki Hamada; Hirotsugu Ariizumi; Tomoyuki Ishiguro; Ryotaro Ohkuma; Takehiko Sambe; Atsushi Horiike; Chiyo K. Imamura; Eisuke Shiozawa; Satoshi Wada; Junji Tsurutani; Sanju Iwamoto; Naoki Uchida; Yuji Kiuchi; Genshu Tate; Shinichi Kobayashi; Takuya Tsunoda, Medicine, 100(23):e25774 - e25774, Jun. 2021
• Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations., KO Ryo;SHUKUYA Takehito;IMAMURA Chiyo K.;TOKITO Takaaki;SHIMADA Naoko;KOYAMA Ryo;YAMADA Kazuhiko;ISHII Hidenobu;AZUMA Koichi;TAKAHASHI Kazuhisa, Transl Lung Cancer Res, 10(1):183 - 192, Jan. 2021, Peer-reviewed, DOI:10.21037/tlcr-20-824
• Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis., AOGI Kenjiro;TAKEUCHI Hideki;SAEKI Toshiaki;AIBA Keisuke;TAMURA Kazuo;IINO Keiko;IMAMURA Chiyo K.;OKITA Kenji;KAGAMI Yoshikazu;TANAKA Ryuhei;NAKAGAWA Kazuhiko;FUJII Hirofumi;BOKU Narikazu;WADA Makoto;AKECHI Tatsuo;IIHARA Hirotoshi;OHTANI Shoichiro;OKUYAMA Ayako;OZAWA Keiko;KIM Yong-II;SASAKI Hidenori;SHIMA Yasuo;TAKEDA Masayuki;NAGASAKI Eijiro;NISHIDATE Toshihiko;HIGASHI Takehiro;HIRATA Kouichi, Int J Clin Oncol, 26(1):1 - 17, Jan. 2021, Peer-reviewed
• Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application., TAKEUCHI Masashi;IMAMURA Chiyo K.;BOOKA Eisuke;TAKEUCHI Hiroya;MIZUKAMI Takuro;KAWAKAMI Takeshi;FUNAKOSHI Taro;WAKUDA Kazushige;AOKI Yu;HAMAMOTO Yasuo;KITAGO Minoru;KAWAKUBO Hirofumi;BOKU Narikazu;TANIGAWARA Yusuke;KITAGAWA Yuko, Cancer Sci, :e, Dec. 2020, Peer-reviewed
• Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia., INOUE Akiko;IMAMURA Chiyo K.;SHIMADA Hiroyuki;KATAYAMA Daisuke;URABE Keisuke;SUZUKI Ryo;TAKITANI Kimitaka;ASHIDA Akira, J Pediatr Pharmacol Ther, 25(8):742 - 745, Nov. 2020, Peer-reviewed
• Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group., HIRATA Kenro;HAMAMOTO Yasuo;ANDO Masahiko;IMAMURA Chiyo K.;YOSHIMURA Kenichi;YAMAZAKI Kentaro;HIRONAKA Shuichi;MURO Kei, BMC Cancer, 20(1):548, Jun. 2020, Peer-reviewed
• A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide., MATSUMOTO Koji;TAKAHASHI Masato;SATO Kazuhiko;OSAKI Akihiko;TAKANO Toshimi;NAITO Yoichi;MATSUURA Kazuo;AOGI Kenjiro;FUJIWARA Kimiko;TAMURA Kenji;BABA Motoi;TOKUNAGA Shinya;HIRANO Gen;IMOTO Shigeru;MIYAZAKI Chieko;YANAGIHARA Kazuhiro;IMAMURA Chiyo K.;CHIBA Yasutaka;SAEKI Toshiaki, Cancer Med, 9(10):3319 - 3327, May 2020, Peer-reviewed
• Clinical Pharmacology for treatment of pediatric cancer, 今村　知世, 小児外科, 52(5):454 - 459, May 2020
• Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity., KAWAMURA Takahisa;IMAMURA Chiyo K.;KENMOTSU Hirotsugu;TAIRA Tetsuhiko;OMORI Shota;NAKASHIMA Kazuhisa;WAKUDA Kazushige;ONO Akira;NAITO Tateaki;MURAKAMI Haruyasu;MUSHIRODA Taisei;TAKAHASHI Toshiaki;TANIGAWARA Yusuke, Cancer Chemother Pharmacol, 85(3):605 - 614, Mar. 2020, Peer-reviewed
• A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)., Takeshi Suzuki; Yasutaka Sukawa; Chiyo K Imamura; Toshiki Masuishi; Hironaga Satake; Yosuke Kumekawa; Shinsuke Funakoshi; Masahito Kotaka; Yoshiki Horie; Sadayuki Kawai; Hiroyuki Okuda; Tetsuji Terazawa; Chihiro Kondoh; Ken Kato; Kenichi Yoshimura; Hideki Ishikawa; Yasuo Hamamoto; Narikazu Boku; Hiromasa Takaishi; Takanori Kanai, Clinical colorectal cancer, 19(1):13 - 21, Mar. 2020
• CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study., Kenji Tamura; Chiyo K Imamura; Toshimi Takano; Shigehira Saji; Takeharu Yamanaka; Kan Yonemori; Masato Takahashi; Junji Tsurutani; Reiki Nishimura; Kazuhiko Sato; Akira Kitani; Naoto T Ueno; Taisei Mushiroda; Michiaki Kubo; Yasuhiro Fujiwara; Yusuke Tanigawara, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(6):558 - 566, Feb. 2020
• Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study., Kentaro Yamazaki; Shigemi Matsumoto; Chiyo K Imamura; Chiemi Yamagiwa; Ayaka Shimizu; Takayuki Yoshino, Japanese journal of clinical oncology, 50(2):122 - 128, Feb. 2020
• CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study., TAMURA Kenji;IMAMURA Chiyo K.;TAKANO Toshimi;SAJI Shigehira;YAMANAKA Takeharu;YONEMORI Kan;TAKAHASHI Masato;TSURUTANI Junji;NISHIMURA Reiki;SATO Kazuhiko;KITANI Akira;UENO Naoto T.;MUSHIRODA Taisei;KUBO Michiaki;FUJIWARA Yasuhiro;TANIGAWARA Yusuke, J Clin Oncol, :JCO1901412, Dec. 2019, Peer-reviewed
• Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study., YAMAZAKI Kentaro;MATSUMOTO Shigemi;IMAMURA Chiyo K.;YAMAGIWA Chiemi;SHIMIZU Ayaka;YOSHINO Takayuki, Jpn J Clin Oncol, :e, Oct. 2019, Peer-reviewed
• A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)., SUZUKI Takeshi;SUKAWA Yasutaka;IMAMURA Chiyo K.;MASUISHI Toshiki;SATAKE Hironaga;KUMEKAWA Yosuke;FUNAKOSHI Shinsuke;KOTAKA Masahito;HORIE Yoshiki;KAWAI Sadayuki;OKUDA Hiroyuki;TERAZAWA Tetsuji;KONDOH Chihiro;KATO Ken;YOSHIMURA Kenichi;ISHIKAWA Hideki;HAMAMOTO Yasuo;BOKU Narikazu;TAKAISHI Hiromasa;KANAI Takanori, Clin Colorectal Cancer, :e, Oct. 2019, Peer-reviewed
• The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV., Hiroaki Akamatsu; Kiichiro Ninomiya; Hirotsugu Kenmotsu; Masahiro Morise; Haruko Daga; Yasushi Goto; Toshiyuki Kozuki; Satoru Miura; Takaaki Sasaki; Akihiro Tamiya; Shunsuke Teraoka; Yukari Tsubata; Hiroshige Yoshioka; Yoshihiro Hattori; Chiyo K Imamura; Yuki Katsuya; Reiko Matsui; Yuji Minegishi; Hidenori Mizugaki; Kaname Nosaki; Yusuke Okuma; Setsuko Sakamoto; Takashi Sone; Kentaro Tanaka; Shigeki Umemura; Takeharu Yamanaka; Shinsuke Amano; Kazuo Hasegawa; Satoshi Morita; Kazuko Nakajima; Makoto Maemondo; Takashi Seto; Nobuyuki Yamamoto, International journal of clinical oncology, 24(7):731 - 770, Jul. 2019, Peer-reviewed
• Therapeutic drug monitoring of monoclonal antibodies: applicability based on their pharmacokinetic properties, Imamura K. Chiyo, Drug Metab Pharmacokinet, 34(1):14 - 18, Feb. 2019
• Individualized dosing of axitinib based on first-dose area under the concentration-time curve for metastatic renal-cell carcinoma., Miura Y; Imamura CK; Uchino K; Kishida T; Matsubara N; Shinojima T; Kondo K; Hongo F; Yoshimura K; Tanigawara Y; Takano T, Clinical genitourinary cancer, 17(1):e1 - e11, Feb. 2019
• Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen., Toshimichi Nakamura; Kota Toshimoto; Wooin Lee; Chiyo K Imamura; Yusuke Tanigawara; Yuichi Sugiyama, CPT: pharmacometrics & systems pharmacology, 7(7):474 - 482, Jul. 2018
• Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer., Teruo Yamauchi; Jose Rodrigo Espinosa Fernandez; Chiyo K Imamura; Hideko Yamauchi; Hiromitsu Jinno; Maiko Takahashi; Yuko Kitagawa; Seigo Nakamura; Bora Lim; Savitri Krishnamurthy; James M Reuben; Diane Liu; Debasish Tripathy; Helen Chen; Naoko Takebe; Hideyuki Saya; Naoto T Ueno, Oncotarget, 9(6):6872 - 6882, Jan. 2018
• The effects of advanced age and serum alpha(1)-acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients, Hirotsugu Kenmotsu; Chiyo K. Imamura; Akira Ono; Shota Omori; Kazuhisa Nakashima; Kazushige Wakuda; Tetsuhiko Taira; Tateaki Naito; Haruyasu Murakami; Toshiaki Takahashi; Yusuke Tanigawara, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 83(11):2416 - 2425, Nov. 2017
• Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer, Kohei Otsubo; Kaname Nosaki; Chiyo K. Imamura; Hiroaki Ogata; Akitaka Fujita; Shinya Sakata; Fumihiko Hirai; Gouji Toyokawa; Eiji Iwama; Taishi Harada; Takashi Seto; Mitsuhiro Takenoyama; Takeshi Ozeki; Taisei Mushiroda; Mieko Inada; Junji Kishimoto; Kenji Tsuchihashi; Kentaro Suina; Osamu Nagano; Hideyuki Saya; Yoichi Nakanishi; Isamu Okamoto, CANCER SCIENCE, 108(9):1843 - 1849, Sep. 2017
• Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12), Kayoko Yoshida; Chiyo K. Imamura; Kanako Hara; Mayumi Mochizuki; Yusuke Tanigawara, METABOLOMICS, 13(8), Aug. 2017
• Dose-escalation study for the targeting of CD44v(+) cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205), Kohei Shitara; Toshihiko Doi; Osamu Nagano; Chiyo K. Imamura; Takeshi Ozeki; Yuya Ishii; Kenji Tsuchihashi; Shunji Takahashi; Takako E. Nakajima; Shuichi Hironaka; Miki Fukutani; Hiromi Hasegawa; Shogo Nomura; Akihiro Sato; Yasuaki Einaga; Takeshi Kuwata; Hideyuki Saya; Atsushi Ohtsu, GASTRIC CANCER, 20(2):341 - 349, Mar. 2017
• Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study, Eisuke Booka; Chiyo K. Imamura; Hiroya Takeuchi; Yasuo Hamamoto; Daisuke Gomi; Takuro Mizukami; Takashi Ichiyama; Kazunari Tateishi; Tsunehiro Takahashi; Hirofumi Kawakubo; Kenzo Soejima; Narikazu Boku; Yusuke Tanigawara; Yuko Kitagawa, GASTRIC CANCER, 19(3):876 - 886, Jul. 2016
• Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole, Chiyo K. Imamura; Kenichi Furihata; Shinichiro Okamoto; Yusuke Tanigawara, JOURNAL OF CLINICAL PHARMACOLOGY, 56(4):408 - 413, Apr. 2016
• A survey on the usage of the Calvert formula to calculate AUC-based carboplatin dosing in Japan., Imamura CK; Kato Y; Shimokata T; Ando Y; Tanigawara Y, Jpn J Pharm Health Care & Sci (in Japanese), 41(11):759 - 767, Nov. 2015
• The survey for anti-emetic guideline by using questioner, Toshiaki Saeki; Kazuo Tamura; Keisuke Aiba; Kenjiro Aogi; Keiko Lino; Chiyo Imamura; Kenji Eguchi; Kenji Okita; Yoshikazu Kagami; Ryuhei Tanaka; Kazuhiko Nakagawa; Hirofumi Fujii; Narikazu Boku; Kazuo Matsuura; Makoto Wada; Tatsuo Akechi; Yuichi Kakudo; Yong-Il Kim; Hide-Nori Sasaki; Yasuo Shima; Masayuki Takeda; Eijiro Nagasaki; Toshihiko Nishidate; Mitsue Saito; Yukino Ashikaga; Yusuke Tanigawara; Koichi Hirata; Chikashi Ishioka; Masahiko Nishiyama, Japanese Journal of Cancer and Chemotherapy, 42(3):305 - 311, Mar. 2015
• Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype, Yuji Miura; Chiyo K. Imamura; Koya Fukunaga; Yoshihiko Katsuyama; Koichi Suyama; Toshikazu Okaneya; Taisei Mushiroda; Yuichi Ando; Toshimi Takano; Yusuke Tanigawara, BMC CANCER, 14, Dec. 2014
• International models of investigator-initiated trials: implications for Japan, E. L. Trimble; J. Ledermann; K. Law; T. Miyata; C. K. Imamura; B. -H. Nam; Y. H. Kim; Y. -J. Bang; M. Michaels; D. Ardron; S. Amano; Y. Ando; T. Tominaga; K. Kurokawa; N. Takebe, ANNALS OF ONCOLOGY, 23(12):3151 - 3155, Dec. 2012
• Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies, Prithviraj Bose; Edward B. Perkins; Connie Honeycut; Martha D. Wellons; Tammy Stefan; James W. Jacobberger; Emmanouil Kontopodis; Jan H. Beumer; Merrill J. Egorin; Chiyo K. Imamura; W. Douglas Figg; Judith E. Karp; Omer N. Koc; Brenda W. Cooper; Selina M. Luger; A. Dimitrios Colevas; John D. Roberts; Steven Grant, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(6):1657 - 1667, Jun. 2012
• Expression changes in arrestin beta 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients, Hiromichi Matsuoka; Tokuzo Arao; Chihiro Makimura; Masayuki Takeda; Hidemi Kiyota; Junji Tsurutani; Yoshihiko Fujita; Kazuko Matsumoto; Hideharu Kimura; Masatomo Otsuka; Atsuko Koyama; Chiyo K. Imamura; Yusuke Tanigawara; Takeharu Yamanaka; Kyoko Tanaka; Kazuto Nishio; Kazuhiko Nakagawa, ONCOLOGY REPORTS, 27(5):1393 - 1399, May 2012
• A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese., Kazuma Kiyotani; Taisei Mushiroda; Tatsuhiko Tsunoda; Takashi Morizono; Naoya Hosono; Michiaki Kubo; Yusuke Tanigawara; Chiyo K Imamura; David A Flockhart; Fuminori Aki; Koichi Hirata; Yuichi Takatsuka; Minoru Okazaki; Shozo Ohsumi; Takashi Yamakawa; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu, Human molecular genetics, 21(7):1665 - 72, Apr. 2012
• Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients., Kazuma Kiyotani; Taisei Mushiroda; Chiyo K Imamura; Yusuke Tanigawara; Naoya Hosono; Michiaki Kubo; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu, Breast cancer research and treatment, 131(1):137 - 45, Jan. 2012
• Prospective Study Evaluating the Plasma Concentrations of Twenty-six Cytokines and Response to Morphine Treatment in Cancer Patients, Chihiro Makimura; Tokuzo Arao; Hiromichi Matsuoka; Masayuki Takeda; Hidemi Kiyota; Junji Tsurutani; Yoshihiko Fujita; Kazuko Matsumoto; Hideharu Kimura; Masatomo Otsuka; Atsuko Koyama; Chiyo K. Imamura; Takeharu Yamanaka; Kyoko Tanaka; Kazuto Nishio; Kazuhiko Nakagawa, ANTICANCER RESEARCH, 31(12):4561 - 4568, Dec. 2011
• How can we address cancer care after a natural disaster?, Chiyo K. Imamura; Naoto T. Ueno, NATURE REVIEWS CLINICAL ONCOLOGY, 8(7):387 - 388, Jul. 2011
• Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients., Kazuma Kiyotani; Taisei Mushiroda; Chiyo K Imamura; Naoya Hosono; Tatsuhiko Tsunoda; Michiaki Kubo; Yusuke Tanigawara; David A Flockhart; Zeruesenay Desta; Todd C Skaar; Fuminori Aki; Koichi Hirata; Yuichi Takatsuka; Minoru Okazaki; Shozo Ohsumi; Takashi Yamakawa; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(8):1287 - 93, Mar. 2010
• EXPERIMENTAL THERAPIES Investigator-initiated cancer trials with INDs for approval in Japan, Chiyo K. Imamura; Naoko Takebe; Seigo Nakamura; Hideyuki Saya; Naoto T. Ueno, NATURE REVIEWS CLINICAL ONCOLOGY, 7(3):127 - 128, Mar. 2010
• A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors, Nilofer Azad; Alyssa Perroy; Erin Gardner; Chiyo K. Imamura; Cynthia Graves; Gisele A. Sarosy; Lori Minasian; Herbert Kotz; Miranda Raggio; William D. Figg; Elise C. Kohn, CANCER BIOLOGY & THERAPY, 8(19):1800 - 1805, Oct. 2009
• Preparation of the form for adverse reaction monitoring and grading for chemotherapy regimens based on their adverse reaction profiles reported from clinical trials., Imamura Chiyo; Goda N; Tsuda S; Tanigawara Y, J Jpn Soc Hosp Pharm (in Japanese), 43(6):796-799, 2007
• How tightly can a drug be bound to a protein and still be removable by charcoal hemoperfusion in overdose cases?, CI Kawasaki; R Nishi; S Uekihara; S Hayano; U Kragh-Hansen; CI Kawasaki; M Otagiri, CLINICAL TOXICOLOGY, 43(2):95 - 99, 2005
• Charcoal hemoperfusion in the treatment of phenytoin overdose, C Kawasaki; R Nishi; S Uekihara; S Hayano; N Otagiri, AMERICAN JOURNAL OF KIDNEY DISEASES, 35(2):323 - 326, Feb. 2000
• Concentrations of ciclosporin during pregnancy and immediately after delivery in a renal transplant patient., Kawasaki C; Ishii M; Tomimaru A; Nishi R; Ichimaru S; Kiyota Y; Uekihara S; Hayano S; I S; Matsukane H, Jpn J Ther Drug Monit (in Japanese), 14:242-245, 1997
• フェニトイン中毒における活性炭血液吸着法の有用性, 川崎 知世; 古閑 洋子; 西 玲子; 外牧 潤; 上木原 宗一; 早野 俊一; 小田切 優樹, 中毒研究, 10:379-384, 1997
• Bioavailability of suppository containing omeprazole in healthy volunteers and hemorrhagic ulcer patients., Kawasaki C; Nishi R; Kitada H; Otagiri M, Jpn J Clin Pharmacol Ther (in Japanese), 28:603-608, 1997
• Preparation and evaluation of a suppository dosage form containing omeprazole, Kawasaki C; Nishi R; Otagiri M, Pharm. Sci., 3:431-434, 1997
• Decrease of theophylline plasma concentration and variation of protein binding during hemoperfusion in overdosed patient., Kawasaki C; Jingami S; Nishi R; Uekihara S; Matsukane H; Otagiri M, Jpn J Toxicol (in Japanese), 9:75-80, 1996

Presentations

• 治験で収集されている情報に基づく抗がん薬の適正使用と副作用マネジメント　治験で収集されている薬物動態情報の活用, 今村 知世, 第61回日本癌治療学会学術集会, 21 Oct. 2023
• 健康成人女性を対象としたエクオール含有食品エクエルと乳がん内分泌療法薬の相互作用に関する薬物動態試験, 今村 知世;三邉 武彦;肥田 典子;山崎 太義;水上 拓也;龍 家圭;福永 航也;莚田 泰誠;宮川 春菜;内山 成人;内田 直樹;小林 真一, 第30回日本乳癌学会学術総会, 02 Jul. 2022
• Phase II study of olanzapine for CINV during T-DXd in HER2+ mBC patients: WJOG14320B(ERICA), 酒井 瞳;鶴谷 純司;横江 隆道;今村 知世;松本 光史;岩朝 勤;千葉 康敬;平川 雄士;高野 利実, 第30回日本乳癌学会学術総会, 30 Jun. 2022
• Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity, KAWAMURA Takahisa;IMAMURA Chiyo K.;KENMOTSU Hirotsugu;TAIRA Tetsuhiko;OMORI Shota;NAKASHIMA Kazuhisa;WAKUDA Kazushige;ONO Akira;NAITO Tateaki;MURAKAMI Haruyasu;MUSHIRODA Taisei;TAKAHASHI Toshiaki;TANIGAWARA Yusuke, 第18回日本臨床腫瘍学会学術集会, 18 Feb. 2021, Live Streaming
• 生命倫理審査における臨床薬理の専門性　実施側として審査を受けた経験も踏まえて, 今村　知世, 第40回日本臨床薬理学会学術総会, 06 Dec. 2019, 東京
• What we learned from the tamoxifen pharmacogenomics study, 今村　知世, 第57回日本癌治療学会学術集会, 24 Oct. 2019, 福岡
• Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT., HIRATA Kenro;HAMAMOTO Yasuo;TSUCHIHASHI Kenji;KONDOH Chihiro;YAMAZAKI Kentaro;HIRONAKA Syuichi;ANDO Masahiko;IMAMURA Chiyo K.;YOSHIMURA Kenichi;MURO Kei, ESMO Congress 2019, 27 Sep. 2019, Barcelona
• Dose modification of anticancer drugs for patients with hepatic impairment, 今村　知世, 第17回日本臨床腫瘍学会学術集会, 20 Jul. 2019, 京都
• Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC, IMAMURA Chiyo K.;KENMOTSU Hirotsugu;KAWAMURA Takahisa;OYAKAWA Takuya;ONO Akira;OMORI Shota;NAKASHIMA Kazutoshi;WAKUDA Kazushige;TAIRA Tetsuhiko;NAITO Tateaki;MURAKAMI Haruyasu;YAMAMOTO Nobuyuki;TAKAHASHI Toshiaki;TANIGAWARA Yusuke, 第17回日本臨床腫瘍学会学術集会, 19 Jul. 2019, 京都
• Exposure-response analysis of S-1 in patients with advanced gastric cancer, TAKEUCHI Masashi;IMAMURA Chiyo K.;BOOKA Eisuke;KASAI Hidefumi;KAWAKUBO Hirofumi;BOKU Narikazu;TANIGAWARA Yusuke;KITAGAWA Yuko, 第17回日本臨床腫瘍学会学術集会, 18 Jul. 2019, 京都
• Cancer pharmacotherapy for specoal population, 今村　知世, 第52回がんプロセミナー（7大学連携個別化がん医療実践者養成プラン）, 24 Apr. 2019, 狭山
• Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer, SATAKE Hironaga;SUZUKI Takeshi;IMAMURA Chiyo K.;SUKAWA Yasutaka;MASUISHI Toshiki;KUMEKAWA Yosuke;FUNAKOSHI Shinsuke;KOTAKA Masahito;HORIE Yoshiki;KAWAI Sadayuki;OKUDA Hiroyuki;TERAZAWA Tetsuji;KONDOH Chihiro;KATO Ken;YOSHIMURA Kenichi;ISHIKAWA Hideki;HAMAMOTO Yasuo;BOKU Narikazu;TAKAISHI Hiromasa;KANAI Takanori, AACR Annual Meeting 2019, 02 Apr. 2019, Atlanta